Mylène Jansen

SF biomarker changes upon KJD 349 16 Supplementary Figure 3 : The change of concentration in each analyte over the 6 week distraction period is shown (6 week level - baseline level), for 2 subgroups: responders (those whose change in KOOS 4 over 3 months was ≥ 10 points, i.e. those achieving the MCID for KOOS 4 ); and non-responders (those whose change in KOOS 4 over 3 months was <10 points, i.e. those not achieving the MCID for KOOS 4 ). The bars represent the median and 95% Confidence Intervals for each group. Between group comparisons were by Mann-Whitney U test, * p= 0.02. Abbreviations: MCID, minimal clinically important difference; LTBP2, latent-transforming growth factor beta- binding protein 2; TGF β -1, transforming growth factor beta 1; FGF-2, basic fibroblast growth factor; TIMP-1, tissue inhibitor of metalloproteinases 1; TSG-6, tumor necrosis factor-inducible gene 6 protein; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein 1; IL-8, interleukin 8; MMP3, matrix metalloproteinase-3; KOOS: Knee injury and Osteoarthritis Outcome Score (KOOS 4 is composite measure of 4 domains).